RICHARD J O'REILLY

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
  2. pmc Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias
    Ying Yan
    The Saint Luke s Cancer Institute, 4321 Washington, Suite 4000 Kansas City, Missouri 64111, USA
    J Hematol Oncol 2:51. 2009
  3. doi request reprint Novel strategies for adoptive therapy following HLA disparate transplants
    RICHARD J O'REILLY
    Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 24:381-91. 2011
  4. doi request reprint Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation
    RICHARD J O'REILLY
    The Transplantation and Leukemia Service of the Department of Medicine and the Immunology and Molecular Pharmacology Programs at Memorial Sloan Kettering Cancer Center, United States
    Semin Immunol 22:162-72. 2010
  5. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
  6. pmc T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1335-42. 2011
  7. doi request reprint Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
  8. pmc KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
  9. pmc Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
    Katharine C Hsu
    Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Blood 105:4878-84. 2005
  10. doi request reprint Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia
    Sonali Chaudhury
    Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Br J Haematol 140:644-55. 2008

Research Grants

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
    ..New more predictable strategies are under development, which should allow such therapies to be broadly applicable...
  2. pmc Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias
    Ying Yan
    The Saint Luke s Cancer Institute, 4321 Washington, Suite 4000 Kansas City, Missouri 64111, USA
    J Hematol Oncol 2:51. 2009
    ..Patients whose leukemic blasts grew indolently or whose leukemia cells failed to induce growth had a significantly longer DFS and more favorable clinical course...
  3. doi request reprint Novel strategies for adoptive therapy following HLA disparate transplants
    RICHARD J O'REILLY
    Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 24:381-91. 2011
    ..These approaches may thus provide new, immediately accessible resources for the generation and broad application of immune cell therapies to treat and prevent severe viral diseases post transplant...
  4. doi request reprint Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation
    RICHARD J O'REILLY
    The Transplantation and Leukemia Service of the Department of Medicine and the Immunology and Molecular Pharmacology Programs at Memorial Sloan Kettering Cancer Center, United States
    Semin Immunol 22:162-72. 2010
    ....
  5. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
    ..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen...
  6. pmc T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1335-42. 2011
    ..There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years...
  7. doi request reprint Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings
    Hugo Castro-Malaspina
    The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 14:458-68. 2008
    ....
  8. pmc KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma
    Jeffrey M Venstrom
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7330-4. 2009
    ..We hypothesized that patients with a "missing ligand" KIR-HLA compound genotype may uniquely benefit from autologous hematopoietic stem cell transplantation (HSCT)...
  9. pmc Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
    Katharine C Hsu
    Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Blood 105:4878-84. 2005
    ....
  10. doi request reprint Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia
    Sonali Chaudhury
    Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Br J Haematol 140:644-55. 2008
    ..These are encouraging results of T-cell-depleted transplants from alternative donors using fludarabine-based cytoreduction in 18 high-risk patients with Fanconi anaemia, with no evidence of rejection and minimal GVHD...
  11. pmc Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes
    Juliet N Barker
    Department of Medicine, Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:5045-9. 2010
    ..Such therapy may also be applicable to the treatment of other infections and residual or recurrent malignancy after CBT...
  12. pmc Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)
    Mary Pao
    Memorial Sloan Kettering, New York, New York 10065, USA
    Biol Blood Marrow Transplant 14:1022-30. 2008
    ..Prospective, multicenter trials assessing the best strategy to administer this vaccine and its impact on pneumococcal infections following transplantation are warranted...
  13. pmc Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation
    Junli Yu
    Immunology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 113:3875-84. 2009
    ....
  14. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  15. ncbi request reprint In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene
    Mikhail M Doubrovin
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 67:11959-69. 2007
    ..The hNET-based system described may thus have significant potential as a nonimmunogenic reporter for extended repeated quantitative in vivo imaging of transduced cells in man...
  16. ncbi request reprint [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Eur J Nucl Med Mol Imaging 33:988-97. 2006
    ....
  17. pmc A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy
    Aisha N Hasan
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 183:2837-50. 2009
    ..It may be of particular value for recipients of transplants from HLA-disparate donors...
  18. pmc Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias
    Ekaterina Doubrovina
    Department of Pediatrics, Bone Marrow Transplantation Service and Division of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:1633-46. 2012
    ..This series of immunogenic epitopes of WT-1 should prove useful for immunotherapies targeting WT-1(+) malignancies...
  19. doi request reprint Paroxysmal nocturnal hemoglobinuria in pediatric patients
    Kevin J Curran
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center Bone Marrow Transplant Service, New York, New York, USA
    Pediatr Blood Cancer 59:525-9. 2012
    ..To further characterize the clinical presentation and outcome to treatment we performed a retrospective analysis of pediatric patients with PNH...
  20. doi request reprint Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia
    Rachel Kobos
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 18:473-80. 2012
    ..In addition, the use of a TCD transplantation with BU-MEL-FLU as cytoreduction may decrease the toxicity of transplantation in heavily pretreated patients without an increase in relapse rate...
  21. pmc Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
    Ekaterina Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:2644-56. 2012
    ....
  22. ncbi request reprint Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
    ..No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination supports further investigation into its clinical utility...
  23. pmc An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment
    Lamis K Eldjerou
    Allogeneic Bone Marrow Transplantation, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:3999-4006. 2010
    ..Thus, unit dominance is an in vivo phenomenon probably associated with a graft-versus-graft immune interaction mediated by CD34(-) cells...
  24. ncbi request reprint Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies
    Trudy N Small
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 13:235-44. 2007
    ..For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies...
  25. ncbi request reprint Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies
    Aisha N Hasan
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Discov Med 8:210-8. 2009
    ....
  26. doi request reprint WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions
    Eleanor M Tyler
    Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
    Blood 121:308-17. 2013
    ....
  27. ncbi request reprint Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations
    Sharon R Lewin
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY
    Blood 100:2235-42. 2002
    ..T-cell neogenesis, appropriate to age but delayed in adult recipients of T-cell-depleted allografts, justifies interventions to hasten this process and to stimulate desirable cellular immune responses...
  28. doi request reprint T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 19:208-13. 2013
    ..15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD...
  29. ncbi request reprint Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma
    Ekaterina S Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 171:6891-9. 2003
    ..These results suggest that circulating sMIC in the cancer patients deactivates NK immunity by down-modulating important activating and chemokine receptors...
  30. doi request reprint Targeting the intracellular WT1 oncogene product with a therapeutic human antibody
    Tao Dao
    Molecular Pharmacology and Chemistry Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Sci Transl Med 5:176ra33. 2013
    ..This finding also provides preclinical validation for the strategy of developing therapeutic mAbs targeting intracellular oncogenic proteins...
  31. pmc Use of humanized severe combined immunodeficient mice for human vaccine development
    Gloria C Koo
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Expert Rev Vaccines 8:113-20. 2009
    ..Human immune responses could be elicited and assessed in these humanized SCID mice upon vaccination or sensitization with allogeneic tissues. A translational model is proposed to attain preclinical data for testing human vaccines...
  32. ncbi request reprint Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice
    Lia E Perez
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Exp Hematol 32:300-7. 2004
    ..Herein, we studied the in vivo effects of ad-SDF-1 and of an analogue peptide of SDF-1 (CTCE-0214) on human hematopoiesis in a xenotransplant model...
  33. ncbi request reprint Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets
    Katharine C Hsu
    Immunology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 169:5118-29. 2002
    ..Additional rare haplotypes can be identified, and may have arisen by gene duplication, intergenic recombination, or deletions...
  34. ncbi request reprint Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 94:449-55. 2004
    ..We studied a large number of endometrial carcinomas to determine the range of tumors that express WT1; this could have prognostic and therapeutic significance...
  35. ncbi request reprint Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
    ..Strikingly, the CD4(+)IFN-gamma(+) cell fractions were not cytotoxic against EBV-transformed or allogeneic targets...

Research Grants7

  1. Molecular Targeting of Developmental Cancers in Children
    RICHARD O REILLY; Fiscal Year: 2007
    ....
  2. IL-7 FOR IMMUNE RECOVERY AFTER HEMATOPOIETIC ALLOGRAFTS
    RICHARD O REILLY; Fiscal Year: 2007
    ..End of abstract.) ..
  3. The Immunobiology of Marrow Allografts for Leukemia
    RICHARD O REILLY; Fiscal Year: 2007
    ....
  4. The Immunobiology of Marrow Allografts for Leukemia
    RICHARD O REILLY; Fiscal Year: 2007
    ..abstract_text> ..